Kymera Therapeutics, Inc. Cash Flow Statement
KYMR / Health Care|7 years of annual SEC 10-K data (FY2019-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$233M
FY2025
Free Cash Flow
-$234M
FY2025
Capital Expenditures
$1M
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Kymera Therapeutics, Inc. used $233M in operating cash flow and negative free cash flow of $234M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income | -$311.4M | -$223.9M | -$147.0M | -$154.8M | -$41.2M | -$41.2M | -$41.2M |
| Depreciation & Amortization | $8.3M | $7.4M | $3.6M | $3.0M | $825.0K | $825.0K | $825.0K |
| Operating Cash Flow | -$232.9M | -$194.5M | -$102.8M | -$153.1M | $17.9M | $17.9M | $17.9M |
| Capital Expenditures | $1.4M | $12.8M | $34.5M | $2.8M | $532.0K | $532.0K | $532.0K |
| Free Cash Flow | -$234.3M | -$207.3M | -$137.3M | -$155.9M | $17.4M | $17.4M | $17.4M |
| FCF Margin | -597.6% | -440.5% | -174.7% | -333.0% | 592.1% | 592.1% | - |